372 related articles for article (PubMed ID: 32478678)
1. Correction of muscular dystrophies by CRISPR gene editing.
Chemello F; Bassel-Duby R; Olson EN
J Clin Invest; 2020 Jun; 130(6):2766-2776. PubMed ID: 32478678
[TBL] [Abstract][Full Text] [Related]
2. CRISPR-Editing Therapy for Duchenne Muscular Dystrophy.
Chemello F; Olson EN; Bassel-Duby R
Hum Gene Ther; 2023 May; 34(9-10):379-387. PubMed ID: 37060194
[TBL] [Abstract][Full Text] [Related]
3. CRISPR/Cas correction of muscular dystrophies.
Zhang Y; Nishiyama T; Olson EN; Bassel-Duby R
Exp Cell Res; 2021 Nov; 408(1):112844. PubMed ID: 34571006
[TBL] [Abstract][Full Text] [Related]
4. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.
Hanson B; Wood MJA; Roberts TC
RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516
[TBL] [Abstract][Full Text] [Related]
5. In Vivo Genome Editing Restores Dystrophin Expression and Cardiac Function in Dystrophic Mice.
El Refaey M; Xu L; Gao Y; Canan BD; Adesanya TMA; Warner SC; Akagi K; Symer DE; Mohler PJ; Ma J; Janssen PML; Han R
Circ Res; 2017 Sep; 121(8):923-929. PubMed ID: 28790199
[TBL] [Abstract][Full Text] [Related]
6. Genome Editing of Monogenic Neuromuscular Diseases: A Systematic Review.
Long C; Amoasii L; Bassel-Duby R; Olson EN
JAMA Neurol; 2016 Nov; 73(11):1349-1355. PubMed ID: 27668807
[TBL] [Abstract][Full Text] [Related]
7. CRISPR-Based Therapeutic Gene Editing for Duchenne Muscular Dystrophy: Advances, Challenges and Perspectives.
Chen G; Wei T; Yang H; Li G; Li H
Cells; 2022 Sep; 11(19):. PubMed ID: 36230926
[TBL] [Abstract][Full Text] [Related]
8. Full-length dystrophin restoration via targeted exon integration by AAV-CRISPR in a humanized mouse model of Duchenne muscular dystrophy.
Pickar-Oliver A; Gough V; Bohning JD; Liu S; Robinson-Hamm JN; Daniels H; Majoros WH; Devlin G; Asokan A; Gersbach CA
Mol Ther; 2021 Nov; 29(11):3243-3257. PubMed ID: 34509668
[TBL] [Abstract][Full Text] [Related]
9. Advances in CRISPR/Cas9 Genome Editing for the Treatment of Muscular Dystrophies.
Fatehi S; Marks RM; Rok MJ; Perillat L; Ivakine EA; Cohn RD
Hum Gene Ther; 2023 May; 34(9-10):388-403. PubMed ID: 37119122
[TBL] [Abstract][Full Text] [Related]
10. Toward the correction of muscular dystrophy by gene editing.
Olson EN
Proc Natl Acad Sci U S A; 2021 Jun; 118(22):. PubMed ID: 34074727
[TBL] [Abstract][Full Text] [Related]
11. Enhanced CRISPR-Cas9 correction of Duchenne muscular dystrophy in mice by a self-complementary AAV delivery system.
Zhang Y; Li H; Min YL; Sanchez-Ortiz E; Huang J; Mireault AA; Shelton JM; Kim J; Mammen PPA; Bassel-Duby R; Olson EN
Sci Adv; 2020 Feb; 6(8):eaay6812. PubMed ID: 32128412
[TBL] [Abstract][Full Text] [Related]
12. Gene editing of Duchenne muscular dystrophy using biomineralization-based spCas9 variant nanoparticles.
Li S; Du M; Deng J; Deng G; Li J; Song Z; Han H
Acta Biomater; 2022 Dec; 154():597-607. PubMed ID: 36243370
[TBL] [Abstract][Full Text] [Related]
13. CRISPR Correction of Duchenne Muscular Dystrophy.
Min YL; Bassel-Duby R; Olson EN
Annu Rev Med; 2019 Jan; 70():239-255. PubMed ID: 30379597
[TBL] [Abstract][Full Text] [Related]
14. Restoration of dystrophin expression and correction of Duchenne muscular dystrophy by genome editing.
Aslesh T; Erkut E; Yokota T
Expert Opin Biol Ther; 2021 Aug; 21(8):1049-1061. PubMed ID: 33401973
[No Abstract] [Full Text] [Related]
15. CRISPR-Cas9 Correction of Duchenne Muscular Dystrophy in Mice by a Self-Complementary AAV Delivery System.
Zhang Y; Bassel-Duby R; Olson EN
Methods Mol Biol; 2023; 2587():411-425. PubMed ID: 36401041
[TBL] [Abstract][Full Text] [Related]
16. CRISPR technologies for the treatment of Duchenne muscular dystrophy.
Choi E; Koo T
Mol Ther; 2021 Nov; 29(11):3179-3191. PubMed ID: 33823301
[TBL] [Abstract][Full Text] [Related]
17. Creation of a Novel Humanized Dystrophic Mouse Model of Duchenne Muscular Dystrophy and Application of a CRISPR/Cas9 Gene Editing Therapy.
Young CS; Mokhonova E; Quinonez M; Pyle AD; Spencer MJ
J Neuromuscul Dis; 2017; 4(2):139-145. PubMed ID: 28505980
[TBL] [Abstract][Full Text] [Related]
18. CRISPR-Cpf1 correction of muscular dystrophy mutations in human cardiomyocytes and mice.
Zhang Y; Long C; Li H; McAnally JR; Baskin KK; Shelton JM; Bassel-Duby R; Olson EN
Sci Adv; 2017 Apr; 3(4):e1602814. PubMed ID: 28439558
[TBL] [Abstract][Full Text] [Related]
19. Prime Editing Permits the Introduction of Specific Mutations in the Gene Responsible for Duchenne Muscular Dystrophy.
Happi Mbakam C; Rousseau J; Tremblay G; Yameogo P; Tremblay JP
Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682838
[TBL] [Abstract][Full Text] [Related]
20. CRISPR-Cas9 Gene Therapy for Duchenne Muscular Dystrophy.
Happi Mbakam C; Lamothe G; Tremblay G; Tremblay JP
Neurotherapeutics; 2022 Apr; 19(3):931-941. PubMed ID: 35165856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
